background: inflammatory breast cancer (ibc), a subgroup of locally advanced breast cancer (labc), is diagnosed based on clinical findings, and seems to be different from other types of labc. the purpose of this study was to compare clinicopathological characteristics and outcomes between inflammatory and non-inflammatory labc patients at breast cancer research center (bcrc), tehran, iran. meth...

1. Distinguish between women at various risks of breast cancer recurrence and apply differences to management strategies accordingly. 2. Develop evidence-based treatment plans for the management of early and locally advanced breast cancer. 3. Assess the role of neoadjuvant and adjuvant chemotherapy in early and locally advanced breast cancer. 4. Apply pharmacokinetic and pharmacodynamic princip...

background : the present study aimed to compare the rates of complete clinical and pathologic response to docetaxel, doxorubicin and cyclophosphamide (tac) vs. 5-fluorouracil, doxorubicin and cyclophosphamide (fac) as neoadjuvant chemotherapy in women with locally advanced breast cancer. methods : one hundred women with pathologically confirmed newly diagnosed locally advanced (t3-t4 or n2-n3) ...

Despite wide efforts for early detection of breast cancer using screening mammography, locally advanced breast carcinomas account for a remarkable proportion of all breast carcinomas, particularly in developing countries. Locally advanced breast cancer may have widely different clinical and biological features. Radiotherapy plays an important role in the management of locally advanced breast ca...

The multidisciplinary management of patients with locally advanced breast cancer (LABC) has evolved over the last three decades. The introduction of chemotherapy (CT) and endocrine therapy in conjunction with surgery and radiation therapy (XRT) have changed the natural history of this disease. The authors discuss the role of the taxanes, novel endocrine therapy, and high-dose CT programs in the...

Locally advanced breast cancer represents a wide variety of neoplasms and constitutes approximately 10%-20% of the newly diagnosed breast cancers. These cancers may have widely different clinical and biological characteristics. According to the American Joint Committee on Cancer (AJCC) staging system, all of stage III disease is considered locally advanced. The clinical treatment of locally adv...

PURPOSE Neoadjuvant chemotherapy (NCT) is a standard treatment option for locally advanced breast cancer. However, the lack of an efficient method to predict treatment response and patient prognosis hampers the clinical evaluation of patient eligibility for NCT. An elevated lymphocyte-to-monocyte ratio (LMR) has been reported to be associated with a favorable prognosis for certain hematologic m...